Literature DB >> 25619653

IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.

Paramita Chakrabarty1, Andrew Li2, Carolina Ceballos-Diaz2, James A Eddy3, Cory C Funk3, Brenda Moore2, Nadia DiNunno2, Awilda M Rosario2, Pedro E Cruz2, Christophe Verbeeck4, Amanda Sacino2, Sarah Nix4, Christopher Janus2, Nathan D Price3, Pritam Das4, Todd E Golde5.   

Abstract

Anti-inflammatory strategies are proposed to have beneficial effects in Alzheimer's disease. To explore how anti-inflammatory cytokine signaling affects Aβ pathology, we investigated the effects of adeno-associated virus (AAV2/1)-mediated expression of Interleukin (IL)-10 in the brains of APP transgenic mouse models. IL-10 expression resulted in increased Aβ accumulation and impaired memory in APP mice. A focused transcriptome analysis revealed changes consistent with enhanced IL-10 signaling and increased ApoE expression in IL-10-expressing APP mice. ApoE protein was selectively increased in the plaque-associated insoluble cellular fraction, likely because of direct interaction with aggregated Aβ in the IL-10-expressing APP mice. Ex vivo studies also show that IL-10 and ApoE can individually impair glial Aβ phagocytosis. Our observations that IL-10 has an unexpected negative effect on Aβ proteostasis and cognition in APP mouse models demonstrate the complex interplay between innate immunity and proteostasis in neurodegenerative diseases, an interaction we call immunoproteostasis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25619653      PMCID: PMC4320003          DOI: 10.1016/j.neuron.2014.11.020

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  74 in total

1.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

2.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

Authors:  Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan
Journal:  Arch Neurol       Date:  2008-05-12

3.  Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.

Authors:  K R Bales; T Verina; R C Dodel; Y Du; L Altstiel; M Bender; P Hyslop; E M Johnstone; S P Little; D J Cummins; P Piccardo; B Ghetti; S M Paul
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

4.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

Authors:  G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

5.  Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation.

Authors:  Lars N G Nilsson; Gary W Arendash; Ralph E Leighty; David A Costa; Mark A Low; Marcos F Garcia; Jennifer R Cracciolo; Amyn Rojiani; Xin Wu; Kelly R Bales; Steven M Paul; Huntington Potter
Journal:  Neurobiol Aging       Date:  2004-10       Impact factor: 4.673

Review 6.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

7.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

Authors:  T Wisniewski; E M Castaño; A Golabek; T Vogel; B Frangione
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.

Authors:  Terrence Town; Yasmina Laouar; Christopher Pittenger; Takashi Mori; Christine A Szekely; Jun Tan; Ronald S Duman; Richard A Flavell
Journal:  Nat Med       Date:  2008-06-01       Impact factor: 53.440

9.  Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis.

Authors:  Amanda Hanna; Kayleigh Iremonger; Pritam Das; Dennis Dickson; Todd Golde; Christopher Janus
Journal:  Alzheimers Res Ther       Date:  2012-06-14       Impact factor: 6.982

10.  Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain.

Authors:  Phillip B Jones; Kenneth W Adams; Anete Rozkalne; Tara L Spires-Jones; Tammy T Hshieh; Tadafumi Hashimoto; Christine A F von Armin; Mathew Mielke; Brian J Bacskai; Bradley T Hyman
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

View more
  146 in total

1.  Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis.

Authors:  Karienn S Montgomery; George Edwards; Yona Levites; Ashok Kumar; Catherine E Myers; Mark A Gluck; Barry Setlow; Jennifer L Bizon
Journal:  Hippocampus       Date:  2015-10-19       Impact factor: 3.899

Review 2.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 3.  Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models.

Authors:  Elizabeth E Spangenberg; Kim N Green
Journal:  Brain Behav Immun       Date:  2016-07-06       Impact factor: 7.217

Review 4.  Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.

Authors:  Maria Valeria Catani; Valeria Gasperi; Tiziana Bisogno; Mauro Maccarrone
Journal:  Antioxid Redox Signal       Date:  2017-07-24       Impact factor: 8.401

Review 5.  Innate immune activation in Alzheimer's disease.

Authors:  Ming-Ming Wang; Dan Miao; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

Review 6.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

Review 7.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

Review 8.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Authors:  Yang Shi; David M Holtzman
Journal:  Nat Rev Immunol       Date:  2018-12       Impact factor: 53.106

Review 9.  Inflammatory Cytokines and Alzheimer's Disease: A Review from the Perspective of Genetic Polymorphisms.

Authors:  Fan Su; Feng Bai; Zhijun Zhang
Journal:  Neurosci Bull       Date:  2016-08-27       Impact factor: 5.203

10.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.